NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. Our lead drug candidate, NT-I7, is the only clinical-stage long acting rhIL-7, and is uniquely positioned to address unmet medical needs in Immuno-Oncology and Infectious Diseases such as COVID-19. IL-7 is a fundamental cytokine for lymphocyte development, survival, and memory development. Furthermore, NT-I7 has been shown clinically to have desired PK/PD and safety profiles, making it an ideal combination partner with T-cell targeted therapies as well as vaccines. NT-I7 is being studied in multiple clinical trials and many in collaboration with industry leaders in I-O, including Merck, BMS, and Roche for CPI combination trials. Follow us on Twitter @neoimmunetech
View Top Employees from NeoImmuneTechWebsite | http://www.neoimmunetech.com |
Revenue | $3 million |
Employees | 60 (54 on RocketReach) |
Founded | 2014 |
Address | 2400 Research Blvd. Suite 250, Rockville, Maryland 20850, US |
Phone | (301) 337-2284 |
Fax | (240) 595-6132 |
Technologies |
JavaScript,
HTML,
Font Awesome
+6 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Biotechnology, Business Services, Science and Engineering, Therapeutics, Health Care |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 54171 Companies, NAICS Code 541714 Companies |
Looking for a particular NeoImmuneTech employee's phone or email?
The NeoImmuneTech annual revenue was $3 million in 2024.
Byung Lee is the Senior Vice President and Chief Scientific Officer of NeoImmuneTech.
54 people are employed at NeoImmuneTech.
NeoImmuneTech is based in Rockville, Maryland.
The NAICS codes for NeoImmuneTech are [5417, 541, 54, 54171, 541714].
The SIC codes for NeoImmuneTech are [87, 873].